UroGen Pharma Ltd. (LON:0XOD)

UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of GBP 725.25 million. The enterprise value is 727.11 million.

Market Cap	725.25M
Enterprise Value	727.11M

Important Dates

The next estimated earnings date is Friday, March 13, 2026.

Earnings Date	Mar 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.81M
Shares Outstanding	n/a
Shares Change (YoY)	+18.43%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	2.13%
Owned by Institutions (%)	85.80%
Float	37.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.10
PB Ratio	-8.45
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-5.94
EV / Sales	10.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.08

Financial Position

The company has a current ratio of 3.99

Current Ratio	3.99
Quick Ratio	3.47
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.94
Interest Coverage	-8.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-33.96%
Return on Invested Capital (ROIC)	-101.59%
Return on Capital Employed (ROCE)	-92.65%
Weighted Average Cost of Capital (WACC)	11.16%
Revenue Per Employee	250,182
Profits Per Employee	-426,773
Employee Count	287
Asset Turnover	0.40
Inventory Turnover	1.46

Taxes

In the past 12 months, UroGen Pharma has paid 2.23 million in taxes.

Income Tax	2.23M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +103.83% in the last 52 weeks. The beta is 1.30, so UroGen Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.30
52-Week Price Change	+103.83%
50-Day Moving Average	21.83
200-Day Moving Average	17.62
Relative Strength Index (RSI)	43.62
Average Volume (20 Days)	1,530

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	12.46

Income Statement

In the last 12 months, UroGen Pharma had revenue of GBP 71.80 million and -122.48 million in losses. Loss per share was -2.57.

Revenue	71.80M
Gross Profit	63.15M
Operating Income	-98.43M
Pretax Income	-120.25M
Net Income	-122.48M
EBITDA	-97.53M
EBIT	-98.43M
Loss Per Share	-2.57

Balance Sheet

The company has 94.50 million in cash and 96.67 million in debt, with a net cash position of -1.88 million.

Cash & Cash Equivalents	94.50M
Total Debt	96.67M
Net Cash	-1.88M
Net Cash Per Share	n/a
Equity (Book Value)	-85.86M
Book Value Per Share	-1.84
Working Capital	93.96M

Cash Flow

In the last 12 months, operating cash flow was -102.47 million and capital expenditures -287,905, giving a free cash flow of -102.76 million.

Operating Cash Flow	-102.47M
Capital Expenditures	-287,905
Free Cash Flow	-102.76M
FCF Per Share	n/a

Margins

Gross margin is 87.95%, with operating and profit margins of -137.08% and -170.59%.

Gross Margin	87.95%
Operating Margin	-137.08%
Pretax Margin	-167.47%
Profit Margin	-170.59%
EBITDA Margin	-135.84%
EBIT Margin	-137.08%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.43%
Shareholder Yield	-18.43%
Earnings Yield	-16.89%
FCF Yield	-14.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -6.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.96
Piotroski F-Score	2